Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

Episode Summary

Executive Summary: Heather Turner traces an unconventional path from UCLA law to biotech CEO, showing how curiosity, project management, and willingness to take on hard problems prepared her for leadership. The conversation centers on LB Pharmaceuticals’ LB102, a methylated amisulpride derivative aimed at schizophrenia and other CNS disorders, its phase 2 success, and the difficult financing/IPO path that led to a strong public launch and follow-on capital.

Main Topics: Turner’s career arc from law to biotech CEO (Priority: 5/5): Turner describes growing up in Los Angeles, studying environmental studies and law, then moving from startup-focused legal work into in-house biotech leadership. She emphasizes how each step built skills in curiosity, risk assessment, and team leadership. Why biotech and why in-house leadership (Priority: 4/5): She explains that biotech appealed because patient-focused work can benefit many stakeholders, and that moving in-house let her be part of the team, broaden her responsibilities, and better balance family life. Learning by taking on hard, unfamiliar problems (Priority: 5/5): Turner repeatedly volunteered for new areas—patent litigation, government affairs, portfolio strategy, HR, investor relations, and BD—arguing that biotech rewards people who can learn quickly and work across functions. Carmot Therapeutics and the first CEO experience (Priority: 5/5): Her first CEO role came unexpectedly when she was COO at Carmot. She inherited a company needing to transition from science-driven to development-stage execution, build a public-company-ready organization, and finance late-stage programs before Roche acquired Carmot. LB Pharmaceuticals and LB102’s scientific strategy (Priority: 5/5): LB102 is a methylated derivative of amisulpride designed to cross the blood-brain barrier better, support lower and once-daily dosing, potentially reduce EPS, and allow long-acting injectable development. Clinical data and financing strategy under tough market conditions (Priority: 5/5): She details the phase 2 NOVA1 schizophrenia results, the decision to run a crossover plus IPO in a difficult market, the use of a testing-the-waters process, and a $100 million PIPE that extended runway into 2029. Mental illness drug development realities (Priority: 4/5): Turner highlights placebo response, subjective endpoints, and the role of care partners as major challenges in CNS trials, while underscoring the potential patient and family impact if LB102 succeeds.

Key Arguments: Biotech leadership is built through repeated exposure to new functions, not just formal titles; Turner’s legal background became an advantage because it trained her to manage large, complex projects and understand risk across the business. A patient-first focus can align multiple stakeholders—patients, physicians, employees, investors, and companies—making biotech uniquely meaningful compared with many other industries. Turning amisulpride into LB102 by methylation creates better brain penetration, lower dosing needs, once-daily administration, and IP protection, which collectively improve commercial and clinical feasibility. The phase 2 NOVA1 data were strong enough to justify a bold capital strategy: an IPO sized to fund phase 3 schizophrenia and phase 2 bipolar depression, rather than a smaller stepwise trial. In CNS, placebo effects and subjective symptom scales are major trial risks; successful programs require careful design and operational discipline. Turner believes women in particular may underestimate when they are ready for senior operating roles and should take broader leadership opportunities sooner. Public-market financing can still work in biotech if the valuation is attractive, the investor base understands the long timeline, and the company is transparent about risks and milestones.

Data Points: Countries with amisulpride approval: More than 50 countries - Amisulpride is globally used but was never approved in the U.S. before going generic. Dosing frequency of amisulpride: Twice daily - LB102 is intended to improve on the parent compound by enabling once-daily dosing. Roche acquisition of Carmot: $2.7 billion upfront + $400 million milestones - Turner’s first CEO company, Carmot Therapeutics, was acquired in 2024. Move to the U.S. market for LB102: Never previously approved in the U.S. - The parent benzamide antipsychotic class lacked a U.S. market presence. Phase 2 NOVA1 doses: 50 mg, 75 mg, 100 mg - All three doses showed statistically significant improvement over placebo. LB Pharmaceuticals crossover round: About $150 million - Raised to prepare the company for IPO and later-stage development. Balance sheet at IPO: $14 million - Turner said the company had very limited cash remaining at the time of the IPO. Public company runway: Into Q2 2029 - After the IPO and PIPE, LB had extended financial runway to fund the planned clinical program. PIPE financing: $100 million - Completed after the IPO when a new investor wanted to build a position in the thinly traded stock. Cognitive impairment in schizophrenia: 80% - Turner cited this as a major residual symptom burden and a cross-indication opportunity. Cognitive deficit in bipolar disorder and MDD: 45% to 60% - She used these figures to support expansion beyond schizophrenia. Long-acting injectable potential: Lifecycle opportunity - LB102’s improved pharmacology could support a future injectable formulation.

Pivotal Quotes: "You really have an opportunity to really do something meaningful for patients." — Heather Turner: She explains why serious mental illness is an important and under-discussed area. "I think for women, sometimes we tend to think we need more and more experience before we'll actually pursue that next role." — Heather Turner: She reflects on delayed self-advocacy and readiness for senior operating roles. "We needed to do something pretty bold." — Heather Turner: She justifies pursuing a larger IPO and broader capital plan rather than a smaller incremental trial strategy.

Implications: The episode frames CNS drug development as high-risk but high-impact: if LB102 succeeds, it could become a differentiated, easier-to-take treatment across multiple psychiatric indications and improve adherence for patients and families.